Cytosin-Arabinosid
Infantile Leukemia (Both AML and ALL)
St. Jude Children's Research HospitalPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Infantile Leukemia (Both AML and ALL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Clofarabine St. Jude Children's Research Hospital | Phase 1 | CC |
Sorafenib St. Jude Children's Research Hospital | Phase 1 | CC |
Same molecule, other indications
Cytosin-Arabinosid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →